Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Asset Writedowns and Impairment: 2011-2016

Historic Asset Writedowns and Impairment for Tenax Therapeutics (TENX) over the last 2 years, with Dec 2016 value amounting to $33.3 million.

  • Tenax Therapeutics' Asset Writedowns and Impairment was N/A to $33.3 million in Q4 2016 from the same period last year, while for Dec 2016 it was $35.7 million, marking a year-over-year change of. This contributed to the annual value of $33.3 million for FY2016, which is N/A change from last year.
  • Per Tenax Therapeutics' latest filing, its Asset Writedowns and Impairment stood at $33.3 million for Q4 2016, which was up 3,923.13% from $826,846 recorded in Q1 2014.
  • In the past 5 years, Tenax Therapeutics' Asset Writedowns and Impairment registered a high of $33.3 million during Q4 2016, and its lowest value of $27,758 during Q2 2012.
  • In the last 2 years, Tenax Therapeutics' Asset Writedowns and Impairment had a median value of $17.0 million in 2014 and averaged $17.0 million.
  • Per our database at Business Quant, Tenax Therapeutics' Asset Writedowns and Impairment tumbled by 90.81% in 2012 and then spiked by 2,878.77% in 2013.
  • Tenax Therapeutics' Asset Writedowns and Impairment (Quarterly) stood at $802,736 in 2012, then rose by 3.00% to $826,846 in 2013, then grew by 3.00% to $826,846 in 2014, then reached $33.3 million in 2016.
  • Its Asset Writedowns and Impairment was $33.3 million in Q4 2016, compared to $826,846 in Q1 2014 and $826,846 in Q4 2013.